By Michael A. Carrier (Rutgers Law School)
Brand-name drug companies frequently switch from one version of a drug to another. Sometimes, the switch is made just to keep the generic off the market. Should this anticompetitive “product hopping” be allowed? Surprisingly, several courts have said yes. These courts have found that when the drug company leaves the original version on the market, consumers cannot be harmed since they have a “choice.” This position, however, is at odds with the realities of the pharmaceutical industry, in which doctors prescribe but do not pay for the drug and consumers (or their insurers) pay for but do not choose it.
In this piece, I explain why legislation addressing product hopping is the best option to address this anticompetitive behavior. I focus on the Affordable Prescriptions for Patients Act of 2021, bipartisan legislation that addresses the harms from product hopping while appropriately deferring to any reasonable justifications the drug company could offer. I explain how the legislation is conservative in several ways. I address the industry’s argument that product-hopping legislation harms innovation. And I conclude that legislation can play a crucial role in ensuring that consumers have access to affordable generic medicines.
Featured News
CVS Health Explores Potential Breakup Amid Investor Pressure: Report
Oct 3, 2024 by
CPI
DirecTV Acquires Dish TV, Creating 20 Million-Subscriber Powerhouse
Oct 3, 2024 by
CPI
South Korea Fines Kakao Mobility $54.8 Million for Anti-Competitive Practices
Oct 3, 2024 by
CPI
Google Offers Settlement in India’s Antitrust Case Regarding Smart TVs
Oct 3, 2024 by
CPI
Attorney Challenges NCAA’s $2.78 Billion Settlement in Landmark Antitrust Cases
Oct 3, 2024 by
nhoch@pymnts.com
Antitrust Mix by CPI
Antitrust Chronicle® – Refusal to Deal
Sep 27, 2024 by
CPI
Antitrust’s Refusal-to-Deal Doctrine: The Emperor Has No Clothes
Sep 27, 2024 by
Erik Hovenkamp
Why All Antitrust Claims are Refusal to Deal Claims and What that Means for Policy
Sep 27, 2024 by
Ramsi Woodcock
The Aspen Misadventure
Sep 27, 2024 by
Roger Blair & Holly P. Stidham
Refusal to Deal in Antitrust Law: Evolving Jurisprudence and Business Justifications in the Align Technology Case
Sep 27, 2024 by
Timothy Hsieh